Related News

• Eli Lilly and Company (LLY): One of the Top Stocks to Buy Right Now According to AI | 2026-06-01
  We just covered the 10 Best Stocks to Buy Right Now According to AI and Eli Lilly and Company (NYSE:LLY) ranks 4th on this list. Eli Lilly and Company (NYSE:LLY) is a premier global pharmaceutical corporation dedicated to discovering, developing, and manufacturing innovative human medicines across multiple therapeutic areas. The company’s primary growth catalyst is […]
• A Look At Eli Lilly’s Valuation After Strong Momentum In Share Price And Earnings | 2026-06-01
  Recent performance context for Eli Lilly (LLY) Eli Lilly (LLY) has drawn investor attention after a period where the stock rose about 15% over the past month and about 10% over the past 3 months, alongside strong reported revenue and net income figures. See our latest analysis for Eli Lilly. That recent 14.7% 30 day share price return comes on top of a 48.9% total shareholder return over the past year and a very large 5 year total shareholder return, so momentum has been building over both...
• Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer | 2026-05-31
  /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant...
• Eli Lilly and Company (LLY): A Long Term Stock to Buy | 2026-05-30
  Eli Lilly and Company (NYSE:LLY) is one of the top long-term stocks to buy. On May 25, Eli Lilly and Company (NYSE:LLY) delivered positive Phase 1b Heart-2 study results for VERVE-102, an investigational base-editing therapy designed to deactivate the PCSK9 gene in the liver. The trial results show that VERVE-102 successfully reduced PCSK9 by up […]
• Supreme Court Verdict Tests Eli Lilly Valuation And Legal Risk Outlook | 2026-05-29
  United States Supreme Court upholds a $220 million Medicaid fraud verdict against Eli Lilly under the False Claims Act. Decision stems from a whistleblower case and concludes a 12 year legal dispute. Ruling is described as the first jury verdict against a pharmaceutical company under this statute. Eli Lilly, NYSE: LLY, now has a material legal setback sitting alongside a large market valuation, with the stock recently trading around $1,126.80. The company has very large multi year share...
• Eli Lilly (LLY): Top Healthcare Stock Pick of Claude AI | 2026-05-29
  We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Eli Lilly and Company (NYSE:LLY) ranks #2 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot). Number of Hedge Funds: 137 Eli Lilly and Company (NYSE:LLY) is among the top stock picks of the Claude […]
• Eli Lilly (LLY) Reports Positive Phase 1b Verve-102 Study Results | 2026-05-29
  Eli Lilly and Company (NYSE:LLY) is one of the 12 Most Profitable Stocks to Invest In. On May 25, 2026, Eli Lilly and Company (NYSE:LLY) announced positive Phase 1b Heart-2 study results for Verve-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood […]
• Why Eli Lilly (LLY) Stock Is Trading Up Today | 2026-05-29
  Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the afternoon session after CVS restored Zepbound as a co-preferred option and simultaneously added Lilly's new oral obesity pill Foundayo, making Eli Lilly's full obesity medication portfolio accessible to all three of America's largest pharmacy benefit managers for the first time.
• Why Is Eli Lilly Stock Surging On Thursday? | 2026-05-28
  Eli Lilly (NYSE:LLY) shares jumped on Thursday morning after securing expanded PBM coverage for its blockbuster obesity treatments, Zepbound and Foundayo.
• Eli Lilly (LLY) – Among the 10 Safe Stocks to Buy for the Long Term in 2026 | 2026-05-28
  Eli Lilly and Company (NYSE:LLY) is included among the 10 Safe Stocks to Buy for the Long Term in 2026. On May 26, BofA raised the firm’s price recommendation for Eli Lilly and Company (NYSE:LLY) to $1,251 from $1,133. It reiterated a Buy rating on the shares. The firm said it expects Lilly’s future revenue […]

News source: finlight